

Alfonso Dueñas-Gonzalez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3811316/publications.pdf>

Version: 2024-02-01

145
papers

5,928
citations

81900

39
h-index

85541

71
g-index

147
all docs

147
docs citations

147
times ranked

7688
citing authors

#	ARTICLE	IF	CITATIONS
1	Hereditary diffuse gastric cancer (HDGC). An overview. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101820.	1.5	5
2	Progress in Metabolic Studies of Gastric Cancer and Therapeutic Implications. <i>Current Cancer Drug Targets</i> , 2022, 22, .	1.6	3
3	Drug repurposing for cancer therapy, easier said than done. <i>Seminars in Cancer Biology</i> , 2021, 68, 123-131.	9.6	30
4	Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198957.	2.5	9
5	Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy. <i>Scientific Reports</i> , 2021, 11, 5222.	3.3	7
6	Perspectives on Drug Repurposing. <i>Current Medicinal Chemistry</i> , 2021, 28, 2085-2099.	2.4	22
7	The role of extracellular DNA (exDNA) in cellular processes. <i>Cancer Biology and Therapy</i> , 2021, 22, 267-278.	3.4	12
8	A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma. <i>Revista De Investigacion Clinica</i> , 2021, 73, 362-370.	0.4	2
9	Mouse Model for Efficient Simultaneous Targeting of Glycolysis, Glutaminolysis, and De Novo Synthesis of Fatty Acids in Colon Cancer. <i>Methods in Molecular Biology</i> , 2021, 2174, 45-69.	0.9	4
10	Barriers for Pharmaceutical Innovation With Focus in Cancer Drugs, the Case of Mexico. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 342-352.	1.6	2
11	Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1153-1163.	2.3	19
12	InÂVitro Employment of Recombinant Taenia solium Calreticulin as a Novel Strategy Against Breast and Ovarian Cancer Stem-like Cells. <i>Archives of Medical Research</i> , 2020, 51, 65-75.	3.3	4
13	The combination of orlistat, lonidamine and 6â€ˆdiazoâ€ˆ5â€ˆoxoâ€ˆLâ€ˆnorleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells. <i>Oncology Letters</i> , 2020, 20, 3053-3060.	1.8	8
14	Immunotherapy Treatment Against Cervical Cancer. <i>Revista De Investigacion Clinica</i> , 2020, 72, 231-238.	0.4	3
15	Pharmacodynamics of current and emerging treatments for cervical cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 671-682.	3.3	18
16	Emerging DNA methylation inhibitors for cancer therapy: challenges and prospects. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 27-35.	0.7	7
17	Growth inhibition and transcriptional effects of ribavirin in lymphoma. <i>Oncology Reports</i> , 2019, 42, 1248-1256.	2.6	5
18	Ivermectin as an inhibitor of cancer stemâ€ˆlike cells. <i>Molecular Medicine Reports</i> , 2018, 17, 3397-3403.	2.4	42

#	ARTICLE	IF	CITATIONS
19	Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy. Expert Opinion on Investigational Drugs, 2018, 27, 475-489.	4.1	80
20	Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells. OncoTargets and Therapy, 2018, Volume 11, 8823-8833.	2.0	3
21	Cytotoxic Activity and Structure-Activity Relationship of Triazole-Containing Bis(Aryl Ether) Macrocycles. ChemMedChem, 2018, 13, 1193-1209.	3.2	14
22	Advancing clinical research globally: Cervical cancer research network from Mexico. Gynecologic Oncology Reports, 2018, 25, 90-93.	0.6	8
23	Metabolic tumor volume changes assessed by interval 18fluorodeoxyglucose positron emission tomography-computed tomography for the prediction of complete response and survival in patients with diffuse large B-cell lymphoma. Oncology Letters, 2018, 16, 1411-1418.	1.8	9
24	Epidemiological Data on the Nutritional Status of Cancer Patients Receiving Treatment with Concomitant Chemoradiotherapy, Radiotherapy or Sequential Chemoradiotherapy to the Abdominopelvic Area. Revista De Investigacion Clinica, 2018, 70, 117-120.	0.4	5
25	The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. American Journal of Cancer Research, 2018, 8, 317-331.	1.4	56
26	Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine in cutaneous t-cell lymphoma in HUT78 cells. American Journal of Blood Research, 2018, 8, 5-16.	0.6	11
27	Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study. Expert Opinion on Investigational Drugs, 2017, 26, 481-487.	4.1	23
28	Feasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer. Oncology Letters, 2017, 13, 1905-1910.	1.8	20
29	Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region. Public Health, 2017, 149, 81-88.	2.9	7
30	Mild C(sp) ³ functionalization of dihydrosanguinarine and dihydrochelerythrine for development of highly cytotoxic derivatives. European Journal of Medicinal Chemistry, 2017, 138, 1-12.	5.5	7
31	Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP ₂) as epigenetic treatment for myelodysplastic syndrome (MDS). Annals of Hematology, 2017, 96, 1825-1832.	1.8	20
32	Understanding tumor anabolism and patient catabolism in cancer-associated cachexia. American Journal of Cancer Research, 2017, 7, 1107-1135.	1.4	15
33	Global strategies for the treatment of early-stage and advanced cervical cancer. Current Opinion in Obstetrics and Gynecology, 2016, 28, 11-17.	2.0	45
34	Clinical presentation and management of uveal melanoma. Molecular and Clinical Oncology, 2016, 5, 675-677.	1.0	23
35	Antitumor Effects of Systemic DNase I and Proteases in an <i>In Vivo</i> Model. Integrative Cancer Therapies, 2016, 15, NP35-NP43.	2.0	19
36	Drug Repurposing for Epigenetic Targets Guided by Computational Methods. , 2016, , 327-357.		19

#	ARTICLE	IF	CITATIONS
37	N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed <i>in silico</i> with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 140-149.	5.2	32
38	Viral inhibitors of NKG2D ligands for tumor surveillance. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1375-1387.	3.4	4
39	The safety of drug treatments for cervical cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 169-180.	2.4	8
40	Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 323-338.	1.8	10
41	G80A Single Nucleotide Polymorphism in Reduced Folate Carrier-1 Gene in a Mexican Population and its Impact on Survival in Patients with Acute Lymphoblastic Leukemia. <i>Revista De Investigacion Clinica</i> , 2016, 68, 154-62.	0.4	2
42	DNA Methyltransferase Inhibitors for Cancer Therapy. , 2015, , 265-290.		11
43	Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids. <i>Oncology Reports</i> , 2015, 34, 1533-1542.	2.6	25
44	Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin. <i>Oncology Reports</i> , 2015, 33, 721-728.	2.6	24
45	Ribavirin as a tri-targeted antitumor repositioned drug. <i>Oncology Reports</i> , 2015, 33, 2384-2392.	2.6	37
46	Emerging drugs for the treatment of cervical cancer. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 165-182.	2.4	21
47	Therapy-related myelodysplastic syndrome. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 655-665.	2.4	9
48	A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 684-689.	3.4	26
49	Discovery and development of DNA methyltransferase inhibitors using <i>in silico</i> approaches. <i>Drug Discovery Today</i> , 2015, 20, 569-577.	6.4	53
50	New molecular targets against cervical cancer. <i>International Journal of Women's Health</i> , 2014, 6, 1023.	2.6	41
51	New pharmacotherapy options for cervical cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 51-60.	1.8	4
52	Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 368-375.	1.5	13
53	The impact of DNA methylation technologies on drug toxicology. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 637-646.	3.3	10
54	Hydralazine+valproate: a repositioned drug combination for the epigenetic therapy of cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1433-1444.	3.3	51

#	ARTICLE	IF	CITATIONS
55	In Vivo Rat Model to Study Horizontal Tumor Progression. <i>Methods in Molecular Biology</i> , 2014, 1165, 175-185.	0.9	2
56	Follow-Up Consultations for Cervical Cancer Patients in a Mexican Cancer Center. Comparison with NCCN Guidelines. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 8749-8752.	1.2	2
57	Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2014, 35, 140-2.	0.2	16
58	Planning cancer control in Latin America and the Caribbean. <i>Lancet Oncology</i> , The, 2013, 14, 391-436.	10.7	394
59	Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2â€“IIB cervical cancer patients. <i>Annals of Oncology</i> , 2013, 24, 2043-2047.	1.2	66
60	A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. <i>Oncotarget</i> , 2013, 4, 502-530.	1.8	152
61	An identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers. <i>Oncogenesis</i> , 2012, 1, e1-e1.	4.9	3
62	Arylamine N-acetyltransferase 2 genotypes in a Mexican population. <i>Genetics and Molecular Research</i> , 2012, 11, 1082-1092.	0.2	13
63	Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: Prognostic and predictive factors and the impact of disease stage on outcomes from a prospective randomized phase III trial. <i>Gynecologic Oncology</i> , 2012, 126, 334-340.	1.4	36
64	Epigenetic Therapy With Hydralazine and Magnesium Valproate Reverses Imatinib Resistance in Patients With Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 207-212.	0.4	26
65	Emerging drugs for cervical cancer. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 203-218.	2.4	14
66	Cancer Progression Mediated by Horizontal Gene Transfer in an In Vivo Model. <i>PLoS ONE</i> , 2012, 7, e52754.	2.5	114
67	DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e29181.	2.5	44
68	Late recurrence of cervical cancer: a report of 16 cases. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2012, 33, 485-8.	0.2	1
69	Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix. <i>Journal of Clinical Oncology</i> , 2011, 29, 1678-1685.	1.6	395
70	Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotypeâ€“genotype correlation with the sulfamethazine test. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 894-901.	1.5	12
71	Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma. <i>Oncology Reports</i> , 2011, 25, 399-407.	2.6	22
72	Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. <i>International Journal of Oncology</i> , 2011, 39, 1491-9.	3.3	29

#	ARTICLE	IF	CITATIONS
73	Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. <i>Annals of Hematology</i> , 2011, 90, 379-387.	1.8	63
74	Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer. <i>Medical Oncology</i> , 2011, 28, 1507-1513.	2.5	13
75	A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. <i>Medical Oncology</i> , 2011, 28, 540-546.	2.5	109
76	Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1601-1612.	3.3	7
77	Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2011, 49, 519-524.	0.6	18
78	F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma. <i>Revista De Investigacion Clinica</i> , 2011, 63, 227-35.	0.4	9
79	Pharmacogenetics and pharmacoepigenetics of gemcitabine. <i>Medical Oncology</i> , 2010, 27, 1133-1143.	2.5	23
80	Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides. <i>Case Reports in Medicine</i> , 2010, 2010, 1-4.	0.7	8
81	Pharmacotherapy Options for Locally Advanced and Advanced Cervical Cancer. <i>Drugs</i> , 2010, 70, 403-432.	10.9	16
82	Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2010, 31, 386-91.	0.2	24
83	Molecular Modeling and Molecular Dynamics Studies of Hydralazine with Human DNA Methyltransferase...1. <i>ChemMedChem</i> , 2009, 4, 792-799.	3.2	104
84	Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer. <i>Medical Oncology</i> , 2009, 26, 210-214.	2.5	20
85	Lack in Efficacy for Imatinib Mesylate as Second-Line Treatment of Recurrent or Metastatic Cervical Cancer Expressing Platelet-Derived Growth Factor Receptor β . <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1632-1637.	2.5	34
86	Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2009, 30, 527-30.	0.2	12
87	Thiopurine S-methyltransferase Gene (TMPT) polymorphisms in a Mexican population of healthy individuals and leukemic patients. <i>Medical Oncology</i> , 2008, 25, 56-62.	2.5	20
88	Second hit in cervical carcinogenesis process: involvement of wnt/beta catenin pathway. <i>International Archive of Medicine</i> , 2008, 1, 10.	1.2	63
89	The prince and the pauper. A tale of anticancer targeted agents. <i>Molecular Cancer</i> , 2008, 7, 82.	19.2	73
90	Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. <i>Cancer Treatment Reviews</i> , 2008, 34, 206-222.	7.7	314

#	ARTICLE	IF	CITATIONS
91	The Epigenetic Origin of Aneuploidy. <i>Current Genomics</i> , 2008, 9, 43-50.	1.6	62
92	Concurrent chemoradiation with carboplatin for elderly, diabetic and hypertensive patients with locally advanced cervical cancer. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2008, 29, 608-12.	0.2	21
93	A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. <i>Annals of Oncology</i> , 2007, 18, 1529-1538.	1.2	206
94	The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. <i>Virology Journal</i> , 2007, 4, 18.	3.4	57
95	The prognostic significance of leukocytosis in cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 465-470.	2.5	28
96	Treatment of the Adenocarcinoma of the Esophagogastric Junction at a Single Institution in Mexico. <i>Annals of Surgical Oncology</i> , 2007, 14, 1439-1448.	1.5	8
97	Radiation-sparing managements for cervical cancer: a developing countries perspective. <i>World Journal of Surgical Oncology</i> , 2006, 4, 77.	1.9	12
98	Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. <i>Journal of Translational Medicine</i> , 2006, 4, 32.	4.4	76
99	Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. <i>Journal of Translational Medicine</i> , 2006, 4, 55.	4.4	63
100	Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. <i>Cancer Treatment Reviews</i> , 2006, 32, 180-190.	7.7	123
101	A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer. <i>PLoS ONE</i> , 2006, 1, e98.	2.5	126
102	Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results. <i>BMC Women's Health</i> , 2006, 6, 3.	2.0	36
103	Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. <i>Cancer Cell International</i> , 2006, 6, 2.	4.1	111
104	Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. <i>Cancer Cell International</i> , 2006, 6, 22.	4.1	32
105	Radiosensitizers in cervical cancer. Cisplatin and beyond. <i>Radiation Oncology</i> , 2006, 1, 15.	2.7	70
106	Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?. <i>Molecular Cancer</i> , 2006, 5, 27.	19.2	27
107	Distribution of HPV16 and 18 intratypic variants in normal cytology, intraepithelial lesions, and cervical cancer in a Mexican population. <i>Gynecologic Oncology</i> , 2006, 102, 230-235.	1.4	57
108	Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma. <i>International Seminars in Surgical Oncology</i> , 2006, 3, 3.	1.1	31

#	ARTICLE	IF	CITATIONS
109	Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives. <i>Anti-Cancer Drugs</i> , 2005, 16, 923-933.	1.4	23
110	Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: A randomized Phase II study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 817-823.	0.8	69
111	A Clinical and Biological Overview of Gastrointestinal Stromal Tumors. <i>Medical Oncology</i> , 2005, 22, 001-010.	2.5	14
112	Anemia in Cervical Cancer Patients: Implications for Iron Supplementation Therapy. <i>Medical Oncology</i> , 2005, 22, 161-168.	2.5	16
113	Multimodal Treatment of Locally Advanced Cervical Cancer. <i>Archives of Medical Research</i> , 2005, 36, 129-135.	3.3	4
114	A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. <i>BMC Cancer</i> , 2005, 5, 44.	2.6	129
115	Determination of 5-methyl-cytosine and cytosine in tumor DNA of cancer patients. <i>Electrophoresis</i> , 2005, 26, 1057-1062.	2.4	20
116	Computational Studies of 1-Hydrazinophthalazine (Hydralazine) as Antineoplastic Agent. Docking Studies on Methyltransferase. <i>Letters in Drug Design and Discovery</i> , 2005, 2, 282-286.	0.7	27
117	Differential splicing of E6 within human papillomavirus type 18 variants and functional consequences. <i>Journal of General Virology</i> , 2005, 86, 2459-2468.	2.9	36
118	Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. <i>Molecular Cancer</i> , 2005, 4, 22.	19.2	115
119	Epigenetics of cervical cancer. An overview and therapeutic perspectives. <i>Molecular Cancer</i> , 2005, 4, 38.	19.2	183
120	Ether \bar{A} go-go Potassium Channels as Human Cervical Cancer Markers. <i>Cancer Research</i> , 2004, 64, 6996-7001.	0.9	143
121	Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2004, 15, 301-306.	1.2	30
122	Ocular Metastases from Breast Carcinoma. <i>Medical Oncology</i> , 2004, 21, 217-222.	2.5	12
123	Chemoradiation with gemcitabine for cervical cancer in patients with renal failure. <i>Anti-Cancer Drugs</i> , 2004, 15, 761-766.	1.4	20
124	Circulating nucleosomes and response to chemotherapy: An in vitro, in vivo and clinical study on cervical cancer patients. <i>International Journal of Cancer</i> , 2003, 104, 663-668.	5.1	60
125	A PHASE I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 1361-1365.	0.8	29
126	Modern management of locally advanced cervical carcinoma. <i>Cancer Treatment Reviews</i> , 2003, 29, 389-399.	7.7	80

#	ARTICLE	IF	CITATIONS
127	A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation. <i>Annals of Oncology</i> , 2003, 14, 1278-1284.	1.2	85
128	Induction Chemotherapy With Gemcitabine and Oxaliplatin for Locally Advanced Cervical Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 22-25.	1.3	24
129	Long-term results of paclitaxel in FIGO stage III ovarian carcinoma. <i>Anti-Cancer Drugs</i> , 2003, 14, 347-352.	1.4	2
130	Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. <i>Clinical Cancer Research</i> , 2003, 9, 1596-603.	7.0	158
131	Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies. <i>Annals of Oncology</i> , 2002, 13, 1212-1219.	1.2	46
132	Neuroendocrine Marker Expression in Cervical Carcinomas of Non-Small Cell Type. <i>International Journal of Gynecological Pathology</i> , 2002, 21, 368-374.	1.4	21
133	A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma: preliminary report. <i>International Immunopharmacology</i> , 2002, 2, 1007-1016.	3.8	9
134	Neoadjuvant Chemotherapy Followed by Surgery in Locally Advanced Cervical Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2908-2910.	1.6	9
135	Correlation of tumor growth index with early treatment response in cervical carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2002, 21, 57-63.	0.4	1
136	A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma. <i>Annals of Oncology</i> , 2001, 12, 541-547.	1.2	57
137	Weekly Cisplatin/Low-Dose Gemcitabine Combination for Advanced and Recurrent Cervical Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 201-203.	1.3	14
138	Gemcitabine activity in cervical cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 488-492.	2.3	39
139	Membrane proteins in neoplastic and normal uterine cervix. <i>Journal of Experimental and Clinical Cancer Research</i> , 2001, 20, 231-7.	0.4	0
140	Adjuvant high-dose chemotherapy supported by peripheral blood stem cell transplantation for high-risk cervical carcinoma. <i>International Journal of Gynecological Cancer</i> , 1999, 9, 333-336.	2.5	1
141	Bioavailability of Etoposide after Oral Administration of the Solution Marketed for Intravenous Use. <i>Archives of Medical Research</i> , 1999, 30, 212-215.	3.3	9
142	Analysis of nm23-H1 expression in breast cancer. Correlation with p53 expression and clinicopathologic findings. <i>Cancer Letters</i> , 1996, 101, 137-142.	7.2	17
143	Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. <i>Bone Marrow Transplantation</i> , 1996, 17, 809-12.	2.4	37
144	Barriers for Pharmaceutical Innovation With Focus in Cancer Drugs, the Case of Mexico. <i>Therapeutic Innovation and Regulatory Science</i> , 0, , 216847901983901.	1.6	1

#	ARTICLE	IF	CITATIONS
145	Ivermectin: Potential Repurposing of a Versatile Antiparasitic as a Novel Anticancer. , 0, , .		1